57/100Is LEU-Centrus Energy a buy?
Tuesday 14 July 2026
Why now: The stock is repricing sharply in the overnight session (last trade $156.39, down 8.6% versus the $171.11 prior close), which often reflects either a headline-driven reset or a crowded positioning unwind. Separate from the tape, the company has very recent contract confirmation with the DOE that anchors the long-dated commercial-scale HALEU buildout narrative.
Upside: If execution and funding stay on track, the upside is mainly a multi-year re-rating tied to turning government-backed milestones into durable commercial earnings power; analyst target ranges cited by market data providers imply meaningful 12-month upside from recent regular-session prices, but results can be very path-dependent. A more conservative upside frame for a 1+ year holder is: the name can recover much of the current gap if the next earnings update supports timeline and margin confidence.
Risks: The main risk is execution and schedule risk on a long-dated enrichment capacity buildout, where delays, cost inflation, or contracting changes can hit confidence fast. A second risk is valuation compression: if earnings normalize lower or investors rotate away from nuclear-fuel-cycle themes, multiples can fall even if the long-term story remains intact.
Sign up or log in for access
Unlock the full scorecard, detailed analysis, and research notes. Free, no credit card needed.
Scorecard
| Scorecard | 57/100 | |
|---|---|---|
| Company Detail | LEU, Centrus Energy Corp. | |
| Price as at 13 July 2026 | $156.05 | |
| Market cap | $3.1B | |
| Quality and Fundamental Score (100) | ||
| Breakout / Early-Momentum /20 | 0/20 | |
| Rev/EPS Momentum /20 | 13/20 | |
| Business Quality /15 | 12/15 | |
| Balance Sheet /15 | 15/15 | |
| Valuation /10 | 4/10 | |
| Industry Relative Strength /10 | 3/10 | |
| Macro / Sector Tailwind /10 | 10/10 | |
| Growth | ||
| Cash runway | Cash generative | |
| Revenue YoY | +1.5% | |
| EPS YoY | -12.8% | |
| FCF YoY | -4.9% | |
| Gross margin | 26.2% | |
| Valuation & Trend | ||
| Trailing P/E | 62.2x | |
| Forward P/E | 39.6x | |
| RSI (14d) | 42 | |
| vs 50d SMA | -13.3% | |
| Support cushion | −7.3% | |
| Sentiment | ||
| Wall Street verdict | Mixed | |
| News tone | Quiet | |
| Dividend | — | |
How are these colored?
| Metric | Strong metrics | Solid metrics | Selective | Caution | Unfavourable |
|---|---|---|---|---|---|
| Overall score | ≥ 80 | 70-79 | 60-69 | 50-59 | < 50 |
| Business quality /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Balance sheet /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Market cap | ≥ $20B | $5B-$20B | $2B-$5B | $1B-$2B | < $1B |
| Cash runway | ≥ 3 yr or cash generative | 1.5-3 yr | 0.75-1.5 yr | 0.25-0.75 yr | < 0.25 yr |
| Revenue YoY | ≥ 15% | 5-15% | 0-5% | -5-0% | < -5% |
| EPS YoY | ≥ 20% | 5-20% | 0-5% | -5-0% | < -5% |
| FCF YoY | ≥ 10% | 1-10% | 0-1% | -5-0% | < -5% |
| Gross margin | ≥ 60% | 40-60% | 25-40% | 10-25% | < 10% |
| Trailing P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| Forward P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| RSI (14d) | 50-70 | 45-50 or 70-75 | 40-45 or 75-78 | 30-40 or 78-80 | < 30 or > 80 |
| vs 50d SMA | +2% to +15% | 0-2% or 15-25% | -2-0% or 25-35% | -3, 2% or 35-40% | < -3% or > 40% |
| Support cushion | 2-10% above | 0-2% | 10-15% | 15-20% | price below support |
| Wall Street verdict | Aligned | — | Mixed | — | Disagrees |
| News tone | Positive | — | Neutral / Mixed | — | Negative |
| Dividend | Yield ≥ 2% & growing | Growing | Flat payer ≥ 1% | Low / flat | Cutting |
Detailed Analysis, Tuesday 14 July 2026
Amir V.
Todd M.
Receiver of capital expenditure: Yes, A meaningful part of the growth plan is supported by government-funded milestone payments and contract structures that effectively fund capacity buildout and operations tied to deliverables.
Main customers
- U.S. Department of Energy (DOE) / National nuclear programs (Government customer and counterparty for HALEU production and capacity buildout contracts; funding is tied to performance milestones and options.)
- Nuclear utilities and fuel-cycle customers (LEU supply segment) (Commercial customers buying separative work units and uranium deliveries under medium and long-term contracts; Centrus describes a large contracted LEU backlog, with additional contingent commitments tied to future capacity buildout.)
Notable contracts
- DOE HALEU commercial enrichment capacity contract (firm fixed price), $900 million firm fixed price; includes options priced at $17 million per MTU for up to two 5-MTU option deliveries (Signed June 30, 2026; milestone-based payments; delivery by March 2032 of 1 MTU of HALEU UF6 at nominal 19.75% U-235, with DOE options for additional deliveries.)
- Centrus sits at a strategically important choke point in the US nuclear fuel supply chain: domestic uranium enrichment capability, including HALEU, which many advanced reactor designs are expected to require.
- The recent DOE contract structure is a concrete step from “pilot” activity toward commercial-scale milestones, and the company has shown it can deliver HALEU under government programs.
- The tradeoff is that a big part of the value rests on multi-year buildout execution and a market that is still early in commercial demand realization.
Show 2 headlines from the last 7d
Scores 57 out of 100, a mixed overall grade. Balance sheet, sector fit, and business quality scored highest. Earnings trend was fair but not a standout driver. Valuation and relative strength versus its industry weighed on the total. The technical setup is currently poor (no 200-day uptrend signal in the provided tape snapshot, no reclaim/heartbeat, and a large overnight gap down). The overall score is also capped by valuation risk and the reality that a meaningful portion of the upside depends on multi-year execution against government milestones.
Component scores are on the scorecard above.
- The provided daily technical snapshot is weak (no confirmed breakout state and the 200-day trend flag is not positive), and industry-relative strength is also below average.
- The overnight print at $156.39 represents a sharp reset versus the prior close, so near-term momentum is clearly negative and the stock likely needs time to rebuild investor confidence through follow-through news and clean quarterly execution.
- Centrus reported full-year 2025 revenue of $448.7 million, gross profit of $117.5 million, and net income of $77.8 million, and it highlighted a strengthened balance sheet with $2.0 billion of unrestricted cash at year-end 2025.
- In early July 2026 it disclosed a firm fixed price $900 million DOE contract with milestone payments to deploy new domestic commercial HALEU enrichment capacity at Piketon, with delivery obligations running out to March 2032 and DOE options for additional deliveries.
- Key red flags to keep in view: a portion of the long-term upside depends on government option exercise, appropriations, and successful scale-up, and the timeline runs multiple years.
- The historical HALEU operations program also shows that production can be constrained by government-furnished equipment and supply chain bottlenecks (for example, storage cylinder availability was previously cited as a limiting factor), which is a reminder that execution is not fully within Centrus’ control.
Cash runway: Cash generative (latest annual free cash flow is positive).
Upcoming (1-6 months)
- Next quarterly earnings update (market sources show an after-close earnings date in August 2026) for any changes to 2026 guidance, milestone timing, and spend plans tied to the DOE contract.
Ongoing
- Progress against DOE milestone payments and any contract modifications, plus updates on commercial customer commitments that convert from contingent to firm orders.
Risks
- Policy and funding risk: appropriations, changing priorities, or procurement delays could slow milestone payments, reduce option exercise, or shift economics.
- Execution risk: cost inflation, schedule slips, or supply chain constraints could push out the commercialization timeline and compress returns on invested capital.
Breaks the thesis
- A clear management or DOE disclosure that the commercial HALEU capacity buildout is delayed materially beyond stated milestone plans, de-scoped, or no longer expected to transfer into commercially controlled capacity after completion.